Walleye Capital’s Structure Therapeutics GPCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.7M Buy
+118,391
New +$5.56M ﹤0.01% 2211
2026
Q2
– Sell
-21,360
Closed -$1.03M – 4897
2026
Q1
$1.03M Buy
21,360
+21,358
+1,067,900% +$1.46M ﹤0.01% 2049
2025
Q4
$139 Sell
2
-4,488
-100% -$183K ﹤0.01% 4424
2025
Q3
$126K Sell
4,490
-34,183
-88% -$681K ﹤0.01% 3593
2025
Q2
$802K Buy
+38,673
New +$850K ﹤0.01% 2231
2025
Q1
– Sell
-11,656
Closed -$316K – 4573
2024
Q4
$316K Buy
+11,656
New +$414K ﹤0.01% 3379
2024
Q3
– Sell
-400
Closed -$15.7K – 5495
2024
Q2
$15.7K Sell
400
-93,394
-100% -$3.83M ﹤0.01% 5159
2024
Q1
$4.02M Buy
+93,794
New +$3.96M 0.01% 1456

Other funds holding GPCR

Walleye Capital's GPCR Position: Q3 2026 in Review

Walleye Capital opened a new position in Structure Therapeutics (GPCR) in Q3 2026: 118,391 shares worth $3.7M. The stake represents ﹤0.01% of the portfolio and ranks #2211 among its holdings. This is a return to the name: Walleye Capital previously reported a position in GPCR as recently as Q1 2026.

Walleye Capital first reported a position in GPCR in Q1 2024 and has held it in 8 quarters since. The position peaked at $4.02M in Q1 2024. 170 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • Walleye Capital held 118,391 shares of Structure Therapeutics worth $3.7M as of Q3 2026.
  • Structure Therapeutics was a new Walleye Capital position in Q3 2026.
  • Structure Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #2211 holding.
  • Walleye Capital first reported a position in Structure Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Walleye Capital's Structure Therapeutics position peaked at $4.02M in Q1 2024.
  • 170 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.